You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 120 No. 10, October 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (57)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Late Relapse From Cutaneous Stage I Malignant Melanoma

Helen M. Shaw, PhD; Craig W. Beattie, PhD; William H. McCarthy, FRACS, MEd; Gerald W. Milton, FRCS, FRACS

Arch Surg. 1985;120(10):1155-1159.


Abstract

• In 1,283 patients with cutaneous stage I malignant melanoma who had ten or more years of follow-up, the incidence of late recurrence (first evidence of metastases occurring ten or more years after melanoma diagnosis) was 2.7%. None of the factors of prognostic importance (anatomic site, tumor thickness, ulcerative state of primary lesion, or initial surgical treatment) proved useful in predicting those patients with late recurrence. There was no sex or age difference in either incidence of late recurrence or prognosis subsequent to recurrence. Prognosis subsequent to late recurrence depended on the site of the recurrence. Survival after distant metastases became evident was extremely short. However, in the majority (53%) of patients, late recurrence was local and survival subsequent to treatment of these metastases was often protracted, emphasizing the importance of long-term follow-up in all patients with cutaneous melanoma.

(Arch Surg 1985;120:1155-1159)



Author Affiliations

From the Sydney Melanoma Unit, Department of Surgery, University of Sydney, Camperdown, Australia (Dr Shaw and Professors McCarthy and Milton); and the Division of Surgical Oncology, University of Illinois School of Medicine, Chicago (Dr Beattie).


Footnotes

Accepted for publication May 7, 1985.

Reprint requests to Sydney Melanoma Unit, Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2050, Australia (Dr Shaw).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Meng et al.
Clin. Cancer Res. 2004;10:8152-8162.
ABSTRACT | FULL TEXT  

Detection and characterization of carcinoma cells in the blood
Racila et al.
Proc. Natl. Acad. Sci. USA 1998;95:4589-4594.
ABSTRACT | FULL TEXT  

Recurrence Patterns and Outcome in 1019 Patients Undergoing Axillary or Inguinal Lymphadenectomy for Melanoma
Gadd and Coit
Arch Surg 1992;127:1412-1416.
ABSTRACT  

Prognosis After Initial Recurrence of Cutaneous Melanoma
Markowitz et al.
Arch Surg 1991;126:703-708.
ABSTRACT  

Serial Determinations of Melanoma Tumor--Associated Antigen and Antibody in Patients With Stage I Melanoma
Wong et al.
Arch Surg 1986;121:1342-1345.
ABSTRACT  

Prognosis in Melanoma: What Have We Learned?
Koh
Arch Dermatol 1986;122:993-994.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.